There is no excerpt because this is a protected post.
HTA Council Preliminary Recommendation on Aflibercept, Ranibizumab, and Dexamethasone Implant for the Treatment of Retinal Diseases
As of 27 January 2026, the HTA Council has completed the evidence appraisal on the assessment of the following drugs for their respective indications, for possible government financing: The HTA Council hereby releases its preliminary recommendation on the said health technologies for stakeholder feedback and comments from 27 January to 10 February 2026. These health technologies were continue reading : HTA Council Preliminary Recommendation on Aflibercept, Ranibizumab, and Dexamethasone Implant for the Treatment of Retinal Diseases
HTA Council Preliminary Recommendation on Meningococcal Polysaccharide Groups A, C, W-135 And Y conjugate vaccine for active immunization of individuals from the age of 6 weeks against invasive meningococcal diseases caused by 𝙉𝙚𝙞𝙨𝙨𝙚𝙧𝙞𝙖 𝙢𝙚𝙣𝙞𝙣𝙜𝙞𝙩𝙞𝙙𝙞𝙨 group A, C, W-135 and Y
Update as of 09 February 2026: Since the public consultation and appeals period for the HTA Council Preliminary Recommendation on Meningococcal Polysaccharide Groups A, C, W-135 And Y conjugate vaccine for active immunization of individuals from the age of 6 weeks against invasive meningococcal diseases caused by 𝙉𝙚𝙞𝙨𝙨𝙚𝙧𝙞𝙖 𝙢𝙚𝙣𝙞𝙣𝙜𝙞𝙩𝙞𝙙𝙞𝙨 group A, C, W-135 and Y continue reading : HTA Council Preliminary Recommendation on Meningococcal Polysaccharide Groups A, C, W-135 And Y conjugate vaccine for active immunization of individuals from the age of 6 weeks against invasive meningococcal diseases caused by 𝙉𝙚𝙞𝙨𝙨𝙚𝙧𝙞𝙖 𝙢𝙚𝙣𝙞𝙣𝙜𝙞𝙩𝙞𝙙𝙞𝙨 group A, C, W-135 and Y
HTA Council Final Recommendation on Ticagrelor (90mg film-coated tablet) as an add-on to aspirin for adults with Acute Coronary Syndrome (ACS)
The Secretary of Health (SOH) acknowledges the final recommendation of the HTA Council on ticagrelor (90 mg film-coated tablet) as an add-on to aspirin for adults with Acute Coronary Syndrome (ACS) (date of receipt of acknowledgment: 13 January 2026). As a final recommendation, the HTA Council does not recommend the government financing of ticagrelor as continue reading : HTA Council Final Recommendation on Ticagrelor (90mg film-coated tablet) as an add-on to aspirin for adults with Acute Coronary Syndrome (ACS)
HTA Council Final Recommendation on Ceftaroline fosamil (600 mg powder for concentrate for solution for injection) for the treatment of community-acquired pneumonia (CAP) in the pediatric population
The Secretary of Health (SOH) acknowledges the final recommendation of the HTA Council on ceftaroline fosamil (600 mg powder for concentrate for solution for injection) for the treatment of community-acquired pneumonia (CAP) in the pediatric population (date of receipt of acknowledgment: 13 January 2026). As a final recommendation, the HTA Council does not recommend the continue reading : HTA Council Final Recommendation on Ceftaroline fosamil (600 mg powder for concentrate for solution for injection) for the treatment of community-acquired pneumonia (CAP) in the pediatric population